Comparing the diagnostic efficacy of [18F]FDG PET/CT and [18F]FDG PET/MRI for detecting bone metastases in breast cancer: a meta-analysis
By: Longjie Xia, Jianqin Lai, Di Huang, Shenghui Qiu, Huiqiong Hu, Yunxiang Luo and Jie Cao
References
- Torre LA, Islami F, Siegel RL, Ward EM, Jemal A. Global cancer in women: burden and trends. Cancer Epidemiol Biomarkers Prev 2017; 26: 444–57. doi: 10.1158/1055-9965.Epi-16-0858
- Ahmed A, Glynne-Jones R, Ell PJ. Skeletal scintigraphy in carcinoma of the breast – a ten year retrospective study of 389 patients. Nucl Med Commun 1990; 11: 421–6. doi: 10.1097/00006231-199006000-00004
- Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 1998; 16: 2038–44. doi: 10.1200/jco.1998.16.6.2038
- Roberts CC, Daffner RH, Weissman BN, Bancroft L, Bennett DL, Blebea JS, et al. ACR appropriateness criteria on metastatic bone disease. J Am Coll Radiol 2010; 7: 400–9. doi: 10.1016/j.jacr.2010.02.015
- Rong J, Wang S, Ding Q, Yun M, Zheng Z, Ye S. Comparison of 18 FDG PET-CT and bone scintigraphy for detection of bone metastases in breast cancer patients. A meta-analysis. Surg Oncol 2013; 22: 86–91. doi: 10.1016/j.suronc.2013.01.002
- Evangelista L, Cuppari L, Burei M, Zorz A, Caumo F. Head-to-head comparison between 18F-FDG PET/CT and PET/MRI in breast cancer. Clin Transl Imaging 2019; 7: 99–104. doi: 10.1007/s40336-019-00319-2
- Choi YJ, Shin YD, Kang YH, Lee MS, Lee MK, Cho BS, et al. The Effects of pre-operative (18)F-FDG PET/CT in breast cancer patients in comparison to the conventional imaging Study. J Breast Cancer 2012; 15: 441–8. doi: 10.4048/jbc.2012.15.4.441
- Evangelista L, Cervino AR, Ghiotto C, Al-Nahhas A, Rubello D, Muzzio PC. Tumor marker-guided PET in breast cancer patients-a recipe for a perfect wedding: a systematic literature review and meta-analysis. Clin Nucl Med 2012; 37: 467–74. doi: 10.1097/RLU.0b013e31824850b0
- Botsikas D, Bagetakos I, Picarra M, Da Cunha Afonso Barisits AC, Boudabbous S, Montet X, et al. What is the diagnostic performance of 18-FDG-PET/MR compared to PET/CT for the N- and M-staging of breast cancer? Eur Radiol 2018; 29: 1787–98. doi: 10.1007/s00330-018-5720-8
- Melsaether AN, Raad RA, Pujara AC, Ponzo FD, Pysarenko KM, Jhaveri K, et al. Comparison of whole-body (18)F FDG PET/MR imaging and whole-body (18)F FDG PET/CT in terms of lesion detection and radiation dose in patients with breast cancer. Radiology 2016; 281: 193–202. doi: 10.1148/radiol.2016151155
- Sawicki LM, Grueneisen J, Schaarschmidt BM, Buchbender C, Nagarajah J, Umutlu L, et al. Evaluation of 18F-FDG PET/MRI, 18F-FDG PET/CT, MRI, and CT in whole-body staging of recurrent breast cancer. Eur J Radiol 2016; 85: 459–65. doi: 10.1016/j.ejrad.2015.12.010
- McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM, Clifford T, et al. Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement. Jama 2018; 319: 388–96. doi: 10.1001/jama.2017.19163
- Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011; 155: 529–36. doi: 10.7326/0003-4819-155-8-201110180-00009
- Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539–58. doi: 10.1002/sim.1186
- Catalano OA, Nicolai E, Rosen BR, Luongo A, Catalano M, Iannace C, et al. Comparison of CE-FDG-PET/CT with CE-FDG-PET/MR in the evaluation of osseous metastases in breast cancer patients. Br J Cancer 2015; 112: 1452–60. doi: 10.1038/bjc.2015.112
- Bruckmann NM, Kirchner J, Umutlu L, Fendler WP, Seifert R, Herrmann K, et al. Prospective comparison of the diagnostic accuracy of 18F-FDG PET/MRI, MRI, CT, and bone scintigraphy for the detection of bone metastases in the initial staging of primary breast cancer patients. Eur Radiol 2021; 31: 8714–24. doi: 10.1007/s00330-021-07956-0
- Balci TA, Koc ZP, Komek H. Bone scan or F-18-Fluorodeoxyglucose positron emission tomography/computed tomography; which modality better shows bone metastases of breast cancer? Breast Care 2012; 7: 389–93. doi: 10.1159/000341559
- Hahn S, Heusner T, Kümmel S, Köninger A, Nagarajah J, Müller S, et al. Comparison of FDG-PET/CT and bone scintigraphy for detection of bone metastases in breast cancer. Acta Radiol 2011; 52: 1009–14. doi: 10.1258/ar.2011.100507
- Manohar K, Mittal BR, Senthil R, Kashyap R, Bhattacharya A, Singh G. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma. Nucl Med Commun 2012; 33: 591–6. doi: 10.1097/MNM.0b013e3283516716
- Demir SS, Aktas GE, Yenici FU. A Lesion based and sub-regional comparison of FDG PET/CT and MDP bone scintigraphy in detection of bone metastasis in breast cancer. Curr Med Imaging 2017; 13: 422–30. doi: 10.2174/1573405613666170126121221
- Niikura N, Hashimoto J, Kazama T, Koizumi J, Ogiya R, Terao M, et al. Diagnostic performance of F-18-fluorodeoxyglucose PET/CT and bone scintigraphy in breast cancer patients with suspected bone metastasis. Breast Cancer 2016; 23: 662–7. doi: 10.1007/s12282-015-0621-z
- Riegger C, Herrmann J, Nagarajah J, Hecktor J, Kuemmel S, Otterbach F, et al. Whole-body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patients. Eur J Nucl Med Mol Imaging 2012; 39: 852–63. doi: 10.1007/s00259-012-2077-0
- Rager O, Lee-Felker SA, Tabouret-Viaud C, Felker ER, Poncet A, Amzalag G, et al. Accuracy of whole-body HDP SPECT/CT, FDG PET/CT, and their combination for detecting bone metastases in breast cancer: an intra-personal comparison. Am J Nucl Med Mol Imaging 2018; 8: 159–68. PMID: 30042868
- Hansen JA, Naghavi-Behzad M, Gerke O, Baun C, Falch K, Duvnjak S, et al. Diagnosis of bone metastases in breast cancer: lesion-based sensitivity of dual-timepoint FDG-PET/CT compared to low-dose CT and bone scintigraphy. PLoS ONE 2021; 16: e0260066. doi: 10.1371/journal.pone.0260066
- Niikura N, Costelloe CM, Madewell JE, Hayashi N, Yu TK, Liu J, et al. FDG-PET/CT compared with conventional imaging in the detection of distant metastases of primary breast cancer. Oncologist 2011; 16: 1111–9. doi: 10.1634/theoncologist.2011-0089
- Shawky M, Ali ZAE, Hashem DH, Houseni M. Role of positron-emission tomography/computed tomography (PET/CT) in breast cancer. Egipt J Radiol Nucl Med 2020; 51: 125. doi: 10.1186/s43055-020-00244-9
- Teke F, Teke M, Inal A, Kaplan MA, Kucukoner M, Aksu R, et al. Significance of hormone receptor status in comparison of 18F-FDG-PET/CT and 99mTc-MDP bone scintigraphy for evaluating bone metastases in patients with breast cancer: single center experience. Asian Pac J Cancer Prev 2015; 16: 387–91. doi: 10.7314/apjcp.2015.16.1.387
- Zhang C, Liang Z, Liu W, Zeng X, Mo Y. Comparison of whole-body 18F-FDG PET/CT and PET/MRI for distant metastases in patients with malignant tumors: a meta-analysis. BMC Cancer 2023; 23: 37. doi: 10.1186/s12885-022-10493-8
- Wu LM, Gu HY, Zheng J, Xu X, Lin LH, Deng X, et al. Diagnostic value of whole-body magnetic resonance imaging for bone metastases: a systematic review and meta-analysis. J Magn Reson Imaging 2011; 34: 128–35. doi: 10.1002/jmri.22608
- Bruckmann NM, Morawitz J, Fendler WP, Ruckhäberle E, Bittner AK, Giesel FL, et al. A role of PET/MR in breast cancer? Semin Nucl Med 2022; 52: 611–8. doi: 10.1053/j.semnuclmed.2022.01.003
- Tabouret-Viaud C, Botsikas D, Delattre BM, Mainta I, Amzalag G, Rager O, et al. PET/MR in breast cancer. Semin Nucl Med 2015; 45: 304–21. doi: 10.1053/j.semnuclmed.2015.03.003
- Pfannenberg C, Schwenzer N. Whole-body staging of malignant melanoma: advantages, limitations and current importance of PET-CT, whole-body MRI and PET-MRI. Radiologe 2015; 55: 120–6. doi: 10.1007/s00117-014-2762-z
- Tunariu N, Blackledge M, Messiou C, Petralia G, Padhani A, Curcean S, et al. What's new for clinical whole-body MRI (WB-MRI) in the 21st century. Br J Radiol 2020; 93: 20200562. doi: 10.1259/bjr.20200562
Language: English
Page range: 299 - 309
Submitted on: Apr 1, 2023
Accepted on: Jun 15, 2023
Published on: Jul 26, 2023
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Related subjects:
© 2023 Longjie Xia, Jianqin Lai, Di Huang, Shenghui Qiu, Huiqiong Hu, Yunxiang Luo, Jie Cao, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution 4.0 License.